DECIBEL THERAPEUTICS INC's ticker is DBTX and the CUSIP is 24343R106. A total of 44 filers reported holding DECIBEL THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.25 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2023 | $12,087,787 | +27.5% | 3,139,685 | 0.0% | 66.30% | +480.1% |
Q1 2023 | $9,481,849 | +47.3% | 3,139,685 | 0.0% | 11.43% | +126.6% |
Q4 2022 | $6,436,354 | -40.7% | 3,139,685 | 0.0% | 5.04% | +6.3% |
Q3 2022 | $10,863,000 | -17.8% | 3,139,685 | 0.0% | 4.74% | -12.3% |
Q2 2022 | $13,218,000 | +38.5% | 3,139,685 | 0.0% | 5.41% | +108.7% |
Q1 2022 | $9,545,000 | -34.6% | 3,139,685 | 0.0% | 2.59% | -29.1% |
Q4 2021 | $14,600,000 | -39.7% | 3,139,685 | 0.0% | 3.65% | -20.5% |
Q3 2021 | $24,207,000 | -10.3% | 3,139,685 | 0.0% | 4.60% | -2.5% |
Q2 2021 | $27,001,000 | -24.3% | 3,139,685 | 0.0% | 4.71% | +4.5% |
Q1 2021 | $35,667,000 | – | 3,139,685 | – | 4.51% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
TRV GP III, LLC | 3,139,685 | $27,001,000 | 4.71% |
Samsara BioCapital, LLC | 826,422 | $7,107,000 | 0.88% |
Orbimed Advisors | 4,945,192 | $42,529,000 | 0.43% |
Foresite Capital Management IV, LLC | 297,711 | $2,560,000 | 0.35% |
Alphabet Inc. | 1,636,258 | $14,072,000 | 0.29% |
Casdin Capital, LLC | 1,171,421 | $10,074,000 | 0.26% |
HARVARD MANAGEMENT CO INC | 328,798 | $2,828,000 | 0.16% |
Tibra Equities Europe Ltd | 43,400 | $373,000 | 0.12% |
AlphaCentric Advisors LLC | 45,000 | $387,000 | 0.10% |
Bronte Capital Management Pty Ltd. | 159,462 | $1,371,000 | 0.10% |